Olvimulogene nanivacirepvec is under clinical development by Genelux and currently in Phase I for Malignant Pleural Mesothelioma. According to GlobalData, Phase I drugs for Malignant Pleural Mesothelioma have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Olvimulogene nanivacirepvec’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Olvimulogene nanivacirepvec overview

Olvimulogene nanivacirepvec (GL-ONC1) is under development for the treatment of advanced peritoneal carcinomatosis, high grade epithelial carcinoma, endometrial cancer, ovarian cancer, advanced solid tumor, head and neck cancer, non-small cell lung cancer, small cell lung cancer, breast cancer, melanoma, malignant pleural mesothelioma, fallopian tube cancer, hepatocellular carcinoma and malignant pleural effusion. The therapeutic candidate is administered through intravenous, intrapleural and intraperitoneal  infusion. GL-ONC1 is based on vaccinia virus which is genetically stable oncolytic virus lister strain designed to locate, enter, colonize and destroy cancer cells without harming healthy tissues or organs. It is being developed based on CHOICE platform.

It was also under development for the treatment of acute myeloid leukemia.

Genelux overview

Genelux is a clinical stage biopharmaceutical company. The company develops pipeline of products with applications for cancer detection and therapy. It develops medicines for ovarian cancer, pancreatic cancer and hematologic and solid cancer. The company offers Olvi-Vec, its lead product candidate, that is a changed vaccinia virus that makes use of a triple mode of action: it without delay kills most cancers cells and stimulates a tumor-precise immune reaction and also converts the tumor microenvironment from an immunosuppressive (bloodless state) to an immunoreactive (warm state). It operates in San Diego and Redlands. Genelux is headquartered in Westlake Village, California, the US.

For a complete picture of Olvimulogene nanivacirepvec’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.